Steady-state pharmacokinetics of indinavir in cerebrospinal fluid and plasma among adults with human immunodeficiency virus type 1 infection

Clinical Pharmacology and Therapeutics

Volumn 68, Issue 4, 2000, Pages 367-374

  Haas, David W ^a,b   Stone, Julie ^a,b   Clough, Lisa A ^a,b   Johnson, Benjamin ^a,b   Spearman, Paul ^a,b   Harris, Victoria L ^a,b   Nicotera, Janet ^a,b   Johnson, Regina H ^a,b   Raffanti, Stephen ^a,b   Zhong, Ling ^a,b   Bergqwist, Paul ^a,b   Chamberlin, Steven ^a,b   Hoagland, Vicki ^a,b   Ju, William D ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; GLYCOPROTEIN P; INDINAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CLINICAL ARTICLE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG CLEARANCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MALE; PASSIVE TRANSPORT; PRIORITY JOURNAL; STEADY STATE; VIRUS INHIBITION; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BLOOD-BRAIN BARRIER; DRUG ADMINISTRATION SCHEDULE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; RNA, MESSENGER; RNA, VIRAL;

EID: 0033752243     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.109391     Document Type: Article

References (30)

1. Primary human T-lymphotropic virus type III infection
2. Expression of human immunodeficiency virus antigen (HIV-Ag) in serum and cerebrospinal fluid during acute and chronic infection
3. Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group
4. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain
5. Temporal trends in the incidence of HIV-1-related neurologic diseases: Multicenter AIDS Cohort Study, 1985-1992
6. Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy
7. Remission of progressive multifocal leucoencephalopathy after antiretroviral therapy
8. Treatment of AIDS-associated progressive multifocal leukoencephalopathy with highly active antiretroviral therapy
9. Factors that predict incomplete virological response to protease inhibitor-based antiretroviral therapy
10. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
11. Choroid plexus epithelial expression of MDR1 P glycoprotein and multidrug resistance-associated protein contribute to the blood-cerebrospinalfluid drug-permeability barrier
12. Foscarnet activity on human immunodeficiency virus type 1 in the central nervous system
13. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less
14. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
15. Cerebrospinal fluid indinavir and HIV RNA levels in patients on chronic indinavir therapy
16. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor
17. Pharmacokinetic evaluation of stable piecewise cubic polynomials as numerical integration functions
18. Comparison of Roche Monitor and Organon Teknika NucliSens Assays for quantifying HIV-1 RNA in CSF obtained by ultra-intensive sampling
19. L-735,524: An orally bioavailable human immunodeficiency virus type 1 protease inhibitor
20. L-735,524: The design of a potent and orally bioavailable HIV protease inhibitor
21. Clinically effective HIV-1 protease inhibitors
22. Extrahepatic metabolism of drugs in humans
23. Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1-infected patients with and without AIDS dementia complex
24. Plasma and cerebrospinal fluid saquinavir concentrations in patients receiving combination antiretroviral therapy
25. Ritonavir: Clinical pharmacokinetics and interactions with other anti-HIV agents
26. Antiviral activity of amprenavir in combination with zidovudine/3TC in plasma and CSF in patients with HIV infection
27. Kinetics of HIV-1 entry into cerebrospinal fluid (CSF) in asymptomatic treatment-naive adults as determined by ultra-intensive CSF Sampling
28. Detailed characterization of stavudine pharmacokinetics in cerebrospinal fluid (CSF) and plasma by ultra-intensive CSF sampling
29. Characterization of lamivudine pharmacokinetics in cerebrospinal fluid and plasma by ultraintensive sampling